A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic, Phoenix, Arizona, United States
University of Arizona Cancer Center, Tucson, Arizona, United States
Arkansas Urology, Little Rock, Arkansas, United States
University of California-Davis, Sacramento, California, United States
Mayo Clinic, Jacksonville, Florida, United States
University of Miami, Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
University of Chicago, Chicago, Illinois, United States
Duly Health, Lisle, Illinois, United States
Wichita Urology, Wichita, Kansas, United States
Willis Knighton, Shreveport, Louisiana, United States
Michigan Institute of Urology, Troy, Michigan, United States
Mercy Hospital, St Louis, Missouri, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Northwell Health, Lake Success, New York, United States
NYU Langone, New York, New York, United States
Weill Cornell, New York, New York, United States
Ohio State University, Columbus, Ohio, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Houston Metro Urology, Houston, Texas, United States
Summit Urology, Murray, Utah, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Study leads
Stephen Dale, MD
Study Director
Syncromune, Inc.